The global pre-clinical CROs market expected to be US$ 4,282.42 Mn in 2018 and is predicted to grow at a CAGR of 8.1% during the forecast period 2019 – 2027, to reach US$ 8,412.9 Mn by 2027.
The report highlights the trends prevalent in the global pre-clinical CROs market and the factors driving the market along with those that act as deterrents to its growth.
Europe is the second largest geographic market and is expected to be the second most significant revenue contributor throughout the forecast period. Increasing number of clinical trials, presence of prominent players in the CROs market, and rapid growth in the pharmaceutical companies are likely to be the major factors driving the growth of this market in the European region
Get PDF Sample of this Study @ https://www.theinsightpartners.com/sample/TIPRE00003316/
The major players operating in the pre-clinical CROs market include, Covance, Inc., Charles River, Eurofins Scientific, PRA Health Sciences, WuXi AppTec, Medpace, Inc., Pharmaceutical Product Development, LLC, Parexel International Corporation, ICON Plc, and MD Biosciences among the others.
The global pre-clinical CROs market, based on service, has been segmented into bio-analysis and DMPK studies, toxicology and other services. The toxicology segment held a largest share of the market in 2018. Moreover, the same segment is anticipated to register the highest CAGR in the market during the forecast period as toxicology testing plays a vital role in drug discovery process to evaluate the safety of the drug candidate. Moreover, the test is also one of the most reliable and commonly performed that is taken into consideration for translation of animal responses into an understanding risk among human subjects.
Increasing R&D expenditures and high cost of drug development process in the developed countries have been boosting the market over the years. However, stringent regulations for conduction of clinical trials and variations in the GMP guidelines across countries around the globe are likely to have a negative impact on the growth of the market in the coming years.
The market has witnessed various organic as well as inorganic developments during recent years in the pre-clinical CROs market. For instance, in September 2019, Pharmaceutical Product Development, LLC (PPD) expanded its bio-analytical laboratory in Richmond, Virginia, enhancing immunochemistry, biomarker and chromatography services for biopharmaceutical clients.
Purchase this Comprehensive Research Study @ https://www.theinsightpartners.com/buy/TIPRE00003316/
The major factors driving the growth of outsourcing activities by companies are, cutting costs, need for innovations, increased speed and agility, and accessing specialized knowledge and technologies. A decreasing percentage of profits has become a primary concern for pharmaceutical companies over the past decade. As per an analysis by PhRMA, around $0.8 to $1.7 billion is estimated to be invested by the pharmaceutical industry in R&D to bring a new drug to market. Hence, with an increase in the R&D expenditure, the need for pre-clinical services is expected.
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
Website: www.theinsightpartners.com